EUVIMEDEUVIMED entdecken
Open Access

Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19

A Marco, P Marco

Journal of Thrombosis and Thrombolysis · 2021-08 · 52 (2) · 497-503

DOI: 10.1007/s11239-021-02457-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, online erschienen am 17.04.2021. Verfasst von A Marco und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Department, Hematology Service, University General Hospital in Alicante, Alicante, Spain. marcoana@hotmail.com. Hauptthemen laut MEDLINE: COVID-19, Endothelium, Vascular, Risk Assessment, Thrombophilia. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Endothelium, VascularRisk AssessmentThrombophiliaADAMTS13 ProteinAgedAmbulatory CareBiomarkersCorrelation of DataFemaleFibrin Fibrinogen Degradation ProductsFibrinogenHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesSARS-CoV-2Severity of Illness IndexSpainvon Willebrand Factor

Stichwörter der Autor:innen

ADAMTS13COVID-19Endothelial dysfunctionHypercoagulabilityVon Willebrand factor

Substanzen

BiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment Dvon Willebrand FactorFibrinogenADAMTS13 ProteinADAMTS13 protein, human

Autor:innen und Institutionen

  • Thrombosis and Hemostasis Department, Hematology Service, University General Hospital in Alicante, Alicante, Spain. marcoana@hotmail.com.
  • Biomedical Research Institute in Alicante, Alicante, Spain. marcoana@hotmail.com.
  • Thrombosis and Hemostasis Department, Hematology Service, University General Hospital in Alicante, Alicante, Spain.
  • Biomedical Research Institute in Alicante, Alicante, Spain.
  • Clinical Medicine Department, Miguel Hernández University, Alicante, Spain.

Zitieren

APA

Marco, A., & Marco, P. (2021). Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. Journal of Thrombosis and Thrombolysis, 52(2), 497-503. https://doi.org/10.1007/s11239-021-02457-9

Vancouver

Marco A, Marco P. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. Journal of Thrombosis and Thrombolysis. 2021;52(2):497-503. doi:10.1007/s11239-021-02457-9

BibTeX
@article{Marco2021,
  author = {Marco, A and Marco, P},
  title = {Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2021},
  volume = {52},
  number = {2},
  pages = {497--503},
  doi = {10.1007/s11239-021-02457-9}
}
Kostenlos starten →